The Chinese biotechnology industry is quickly growing at 20% to 30% annually into a an estimated $8.5 billion industry by 2010. The Chinese government has facilitated much of this growth by making biotechnology and drug discovery a top priority in the 11th 5 Year Plan (2006-2010) and making annual contributions of $600 million to advance industry development along with granting incentives such as tax exemptions. Meanwhile, the Chinese pharmaceutical industry is expected to be the 5th largest in the world by 2010.

Sinobiomed Inc. (OTC-BB: SOBM) is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Currently, the company has 10 products approved or in development: threee on the market, one awaiting approval, four in clinical trials, and three in research and development. The company's drugs focus on responding to a wide range of diseases, including malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.

Recombinant protein and enzyme drugs, like those produced by Sinobiomed, are valued for their safety and efficacy. Through partnerships with key research hospitals and institutes, Sinobiomed has build a substantial portfolio of these drugs. Additionally,  Sinobiomed has the ability to manufacture a large quantity of bio-products at extremely low costs through a patented high-yield production process that enhances bioactivity and encourages the highest levels of purity in the drugs.

Investors looking for more information on this industry as well as Sinobiomed can check out their website at Sinobiomed.com. The company's stock is listed on the OTC-BB exchange under the ticker symbol SOBM.

Related Companies
Northwest Biotherapeutics Inc. (NWBO)
China Pharma Holdings Inc. (CPHI)
Sinovac Biotech Ltd. (SVA)
China-Biotics Inc. (CHBT)
Renhuang Pharmaceuticals Inc. (RHGP)